Literature DB >> 8617770

FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis.

A M Chinnaiyan1, C G Tepper, M F Seldin, K O'Rourke, F C Kischkel, S Hellbardt, P H Krammer, M E Peter, V M Dixit.   

Abstract

CD95 (Fas/APO-1) and tumor necrosis factor receptor-1 (TNFR-1) are related molecules that signal apoptosis. Recently, a number of novel binding proteins have been proposed to mediate the signaling of these death receptors. Here we report that an N-terminal truncation of one of these candidate signal transducers, FADD/MORT1, abrogates CD95-induced apoptosis, ceramide generation, and activation of the cell death protease Yama/CPP32. In addition, this dominant-negative derivative of FADD (FADD-DN) blocked TNF-induced apoptosis while not affecting NF- kappaB activation. FADD-DN bound both receptors, and in the case of CD95, it disrupted the assembly of a signaling complex. Taken together, our results functionally establish FADD as the apoptotic trigger of CD95 and TNFR-1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617770     DOI: 10.1074/jbc.271.9.4961

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  129 in total

Review 1.  Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.

Authors:  B G Darnay; B B Aggarwal
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Death effector domain protein PEA-15 potentiates Ras activation of extracellular signal receptor-activated kinase by an adhesion-independent mechanism.

Authors:  J W Ramos; P E Hughes; M W Renshaw; M A Schwartz; E Formstecher; H Chneiweiss; M H Ginsberg
Journal:  Mol Biol Cell       Date:  2000-09       Impact factor: 4.138

3.  T cell-specific FADD-deficient mice: FADD is required for early T cell development.

Authors:  N H Kabra; C Kang; L C Hsing; J Zhang; A Winoto
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 4.  Effector lymphocytes in islet cell autoimmunity.

Authors:  Pere Santamaria
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

5.  Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis.

Authors:  I Herr; D Wilhelm; T Böhler; P Angel; K M Debatin
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

6.  Conditional Fas-associated death domain protein (FADD): GFP knockout mice reveal FADD is dispensable in thymic development but essential in peripheral T cell homeostasis.

Authors:  Yuhang Zhang; Stephen Rosenberg; Hanming Wang; Hongxia Z Imtiyaz; Ying-Ju Hou; Jianke Zhang
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

7.  Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis.

Authors:  Zhaoyu Jin; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2006-08-28       Impact factor: 4.272

8.  Serpins promote cancer cell survival and vascular co-option in brain metastasis.

Authors:  Manuel Valiente; Anna C Obenauf; Xin Jin; Qing Chen; Xiang H-F Zhang; Derek J Lee; Jamie E Chaft; Mark G Kris; Jason T Huse; Edi Brogi; Joan Massagué
Journal:  Cell       Date:  2014-02-27       Impact factor: 41.582

9.  A20 inhibits tumor necrosis factor (TNF) alpha-induced apoptosis by disrupting recruitment of TRADD and RIP to the TNF receptor 1 complex in Jurkat T cells.

Authors:  Kai-Li He; Adrian T Ting
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

10.  Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas.

Authors:  Guoan Chen; Mahaveer S Bhojani; Andrew C Heaford; Daniel C Chang; Bharathi Laxman; Dafydd G Thomas; Laura B Griffin; James Yu; Julia M Coppola; Thomas J Giordano; Lin Lin; David Adams; Mark B Orringer; Brian D Ross; David G Beer; Alnawaz Rehemtulla
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.